Pharmacogenetic approaches to the treatment of alcohol addiction.
Addictive disorders are partly heritable, chronic, relapsing conditions that account for a tremendous disease burden. Currently available addiction pharmacotherapies are only moderately successful, continue to be viewed with considerable scepticism outside the scientific community and have not become widely adopted as treatments. More effective medical treatments are needed to transform addiction treatment and address currently unmet medical needs. Emerging evidence from alcoholism research suggests that no single advance can be expected to fundamentally change treatment outcomes. Rather, studies of opioid, corticotropin-releasing factor, GABA and serotonin systems suggest that incremental advances in treatment outcomes will result from an improved understanding of the genetic heterogeneity among patients with alcohol addiction, and the development of personalized treatments.
Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, USA. markus.heilig@mail. nih.gov
Markus
M
Heilig
David
D
Goldman
Wade
W
Berrettini
Charles P
CP
O'Brien
D000437:Alcoholism / Q000188:drug therapy* / Q000235:genetics*; D000701:Analgesics, Opioid / Q000627:therapeutic use; D006801:Humans; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011957:Receptors, Opioid / Q000235:genetics*
D000701:Analgesics, Opioid; D011957:Receptors, Opioid